MARGINAL ZONE LYMPHOMA

This study is testing a new drug called epcoritamab in Japanese adults with B-cell lymphoma that has come back or stopped responding to standard treatments. The first part of the study aims to find a safe and effective dose. The second part will test that dose, both alone and com…

This study is testing the safety and effectiveness of combining two existing drugs, ibrutinib and rituximab, for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The trial will enroll 175 adults who have not yet received any chemotherapy or i…

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This study is testing how well and how safely a combination of two immunotherapy drugs works for people with certain slow-growing lymphomas who have not yet received treatment. The drugs, glofitamab and obinutuzumab, are designed to help the body's own immune system find and atta…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This large, late-stage study is testing if adding a new drug, tafasitamab, to a standard two-drug regimen (lenalidomide + rituximab) works better for controlling two types of slow-growing lymphoma that have returned or stopped responding to prior treatment. It involves 654 patien…

This study looks back at existing medical scans from nearly 500 people with marginal zone lymphoma. Researchers want to understand how well PET scans work for determining the stage of the disease and predicting how patients will do after treatment. No new tests or treatments are …